Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Septerna, Inc. (SEPN)

Septerna Appoints Rajiv Patni, M.D., as Chief Medical Officer

Neutral Impact 2 of 5 leadership Written later

Septerna, Inc. said its Board of Directors appointed Rajiv Patni, M.D., as Chief Medical Officer, effective August 24, 2026. Dr. Patni previously served as CEO of Judo Bio and as Chief Research and Development Officer at Reata Pharmaceuticals, and the filing says he has more than 25 years of experience in biopharmaceutical research, development and regulatory work.

Key points

  • Appointment effective August 24, 2026; announced in a press release on August 25, 2026
  • Dr. Patni most recently served as Chief Executive Officer of Judo Bio
  • Previously held Chief Medical Officer roles at Global Blood Therapeutics, Portola Pharmaceuticals, Adamas Pharmaceuticals and Actelion Pharmaceuticals
  • Filing states he has contributed to 10 regulatory agency approvals or label expansions

The filing

CompanySepterna, Inc. (SEPN)
Form8-K, current report
Filed with the SECAug 25, 2026, 8:15 AM ET
Accession number0001193125-26-364210

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.